Search
Michigan Paid Clinical Trials
A listing of 2199 clinical trials in Michigan actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
481 - 492 of 2199
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Michigan is currently home to 2199 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Recruiting
This study is researching an experimental drug called linvoseltamab ("study drug").
This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again.
The study consists of 2 phases (Phase 1 and Phase 2):
* In Phase 1, linvoseltamab will be given to a small number of participants to study the side effects of the study drug and to determine the recommended doses of the study drug to be given to participants in Phase 2.
* In... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Relapsed/Refractory Systemic Light Chain Amyloidosis
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Recruiting
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the bra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Melanoma
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Recruiting
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Research Site, Detroit, Michigan
Conditions: Metastatic Non-small Cell Lung Cancer
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/18/2025
Locations: Research Site, Detroit, Michigan
Conditions: Breast Cancer, Early Breast Cancer
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
Recruiting
The goal of this clinical trial is to compare two types of exercise prescriptions in cardiac rehabilitation eligible older adults (60 years or older) with heart disease. The investigators found in a single site pilot trial (insert NCTxxx) that one exercise prescription was better and are now repeating this study in a larger population at two sites (Baystate Medical Center, Springfield MA and Henry Ford Health System, Detroit MI). The main questions the investigators aim to answer are:
1. Compar... Read More
Gender:
ALL
Ages:
Between 60 years and 99 years
Trial Updated:
06/18/2025
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Myocardial Infarction, Coronary Artery Bypass, Percutaneous Coronary Intervention, Heart Failure, Cardiac Valve Surgery
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
Recruiting
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: cGVHD
A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
Recruiting
This study will evaluate the pharmacokinetics (PK) and safety of risdiplam in participants with spinal muscular atrophy (SMA) under 20 days of age at first dose.
Gender:
ALL
Ages:
19 days and below
Trial Updated:
06/18/2025
Locations: University Of Michigan, Ann Arbor, Michigan
Conditions: Muscular Atrophy, Spinal
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Recruiting
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/18/2025
Locations: University of Michigan Hospital, Ann Arbor, Michigan
Conditions: Alpha1-Antitrypsin Deficiency
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
Recruiting
The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/18/2025
Locations: Michigan Center of Medical Research, Farmington Hills, Michigan
Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA)
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
Recruiting
The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to severe symptoms. The main questions it aims to answer are:
* How well cenerimod works on top of the treatment already being administered.
* How safe cenerimod is for adult patients with Systemic Lupus Erythematosus.
Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already be... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/18/2025
Locations: June DO, PC, Lansing, Michigan
Conditions: Lupus Erythematosus, Systemic
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
Recruiting
PE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and right ventricular dilation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Pulmonary Embolism
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Recruiting
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.
Gender:
ALL
Ages:
25 years and below
Trial Updated:
06/18/2025
Locations: University of Michigan - - C.S. Mott Children's Hospital, Ann Arbor, Michigan
Conditions: Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
481 - 492 of 2199
Clinical trials vary in time; in total a single clinical trial may take up to 15 years to complete, and some longitudinal studies ask the participant to stay in touch for follow up questions for a few years after their participation in the study is finished. Depending on the goal and the design of a clinical trial, volunteers may be asked to stay on site for a set amount of nights; this happens because the researchers might want to monitor the participant's at different hours of the day or night. Some clinical research is also setup to compensate individuals, and paid clinical trials are not uncommon.
In Michigan, the University of Michigan division of research has one of the largest clinical trial and research centers in the state, where interested volunteers can enroll in studies for healthy or non-healthy individuals. The Barbara Ann Karmanos cancer institute in Detroit, Michigan also offers clinical trials for many types of cancers for both healthy and non-healthy individuals.
Volunteers who decide to participate in a clinical trial may be compensated for their time and travel expenses during their participation in the study. The compensation will vary depending on the type of study and level of participation required from the volunteer, but paid clinical trials in Michigan are very common.
Participating in a clinical trial is always completely voluntary. This means that nobody, regardless of their condition can be forced to participate nor can they be forced to continue participating in a trial if they wish to withdraw from the study. Non-healthy individuals who decide to enroll in a clinical trial after a suggestion from their doctor or to try an experimental treatment for their condition will never be denied care if they decide to drop out of the study.
Search Clinical Trials in Michigan by Condition
See All Conditions